Predicting proprotein convertase subtilisin kexin type-9 loss of function mutations using plasma PCSK9 concentration.
Sign Up to like & getrecommendations! Published in 2017 at "Journal of clinical lipidology"
DOI: 10.1016/j.jacl.2016.09.015
Abstract: BACKGROUND Low plasma proprotein convertase subtilisin kexin type-9 (PCSK9) concentration has been associated with loss of function (LOF) PCSK9 mutations in several studies. However, the current standard for detection of these LOF mutations is through… read more here.
Keywords: plasma pcsk9; pcsk9 concentration; concentration; lof mutations ... See more keywords
Abstract 565: Effects of PCSK9 Inhibition on Plasma PCSK9 Concentration and Hepatic PCSK9 Expression
Sign Up to like & getrecommendations! Published in 2018 at "Arteriosclerosis, Thrombosis, and Vascular Biology"
DOI: 10.1161/atvb.38.suppl_1.565
Abstract: Background: We previously reported a marked (~7-fold) increase in plasma PCSK9 concentrations in patients treated with monoclonal antibodies blocking PCSK9 action. It is unclear whether this pronou... read more here.
Keywords: plasma pcsk9; 565 effects; pcsk9; abstract 565 ... See more keywords
A cVLP-Based Vaccine Displaying Full-Length PCSK9 Elicits a Higher Reduction in Plasma PCSK9 Than Similar Peptide-Based cVLP Vaccines
Sign Up to like & getrecommendations! Published in 2022 at "Vaccines"
DOI: 10.3390/vaccines11010002
Abstract: Administration of PCSK9-specific monoclonal antibodies, as well as peptide-based PCSK9 vaccines, can lower plasma LDL cholesterol by blocking PCSK9. However, these treatments also cause an increase in plasma PCSK9 levels, presumably due to the formation… read more here.
Keywords: peptide based; full length; cvlp based; pcsk9 ... See more keywords